HOME
ABOUT
RESEARCH
PRODUCTS
INVESTORS
- ASX ANNOUNCEMENTS
  - 2021
  - 2020
  - 2019
  - 2018
  - 2017
  - 2016
- PRESENTATIONS & VIDEOS
  - 2021
  - 2020
  - 2019
  - 2018
  - 2017
  - 2016
  - 2015
- REPORTS
- STOCK INFORMATION
- CORPORATE GOVERNANCE
MEDIA
CONTACT

HOME
ABOUT
RESEARCH
PRODUCTS
INVESTORS
- - ASX ANNOUNCEMENTS
  - - 2021
  - - 2020
  - - 2019
  - - 2018
  - - 2017
  - - 2016
- - PRESENTATIONS & VIDEOS
  - - 2021
  - - 2020
  - - 2019
  - - 2018
  - - 2017
  - - 2016
  - - 2015
- - REPORTS
- - STOCK INFORMATION
- - CORPORATE GOVERNANCE
MEDIA
CONTACT

Category Archives: articles-2015

09 Dec 2015 – Q&A Proactive Investors

By Zelira TherapeuticsDecember 9, 2015articles-2015

09 Dec 2015 – Q&A Proactive Investors

SUBSCRIBE

Leave this field empty if you're human:

Zelira TherapeuticsFollow

Zelira’s Observational Trial will be one of the largest medicinal cannabis studies ever undertaken involving a specific range of products in patients diagnosed with autism. Find out more or register your interest in the trial here https://www.emeraldclinics.com.au/clinical-trials
#ZLD #ZLDAX #ZLDAF

Twitter 1389354330185244673

CONTACT US

Copyright © Zelira Therapeutics. All rights reserved. | Disclaimer.